Physiology Sponsored by
The REVEAL (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL) included 1,200 patients. After 16 weeks, 71 percent of the patients who took the drug showed a 75 percent improvement in skin clearance, compared to 6.5 percent of patients who received a placebo.
The study also found that patients who took the drug continuously were much less likely to experience a worsening of their psoriasis symptoms.
Upper respiratory tract infection, headache and nasopharyngitis were the most common side effects reported by patients in the study.
The REVEAL results will be submitted by drug maker Abbott in its applications to have Humira approved for treatment of psoriasis in the United States and Europe.